Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Payments (Tables)

v3.24.3
Stock-Based Payments (Tables)
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Summary of Status of Stock Options

A summary of the status of stock options as of December 31, 2023 and September 30, 2024 and changes during the nine months ended September 30, 2024 is presented below:

 

 

 

 

 

 

 

 

 

 

 

Aggregate

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

Intrinsic

 

 

 

 

 

 

Average

 

 

Contractual

 

 

Value

 

 

 

Shares

 

 

Exercise Price

 

 

Life (in years)

 

 

(in thousands)

 

Outstanding at December 31, 2023

 

 

1,548,642

 

 

$

34.80

 

 

 

4.5

 

 

$

646

 

Granted

 

 

54,000

 

 

 

5.30

 

 

 

 

 

 

 

Cancelled

 

 

(662,431

)

 

 

31.45

 

 

 

 

 

 

 

Outstanding at September 30, 2024

 

 

940,211

 

 

 

32.00

 

 

 

7.0

 

 

$

 

Exercisable at September 30, 2024

 

 

632,615

 

 

 

40.21

 

 

 

6.5

 

 

$

 

Summary of Status of Restricted Stock Units

A summary of the status of restricted stock units and restricted stock awards as of December 31, 2023 and September 30, 2024 and changes during the nine months ended September 30, 2024 is presented below:

 

 

Shares

 

 

 

 

 

 

Subject to

 

 

 

 

 

 

Restricted Stock

 

 

 

 

 

 

Units and

 

 

Weighted

 

 

 

Restricted Stock

 

 

Average Grant

 

 

 

Awards

 

 

Date Fair Value

 

Outstanding at December 31, 2023

 

 

1,778,614

 

 

$

6.29

 

Granted

 

 

1,726,278

 

 

 

6.43

 

Vested

 

 

(385,530

)

 

 

8.32

 

Forfeited

 

 

(46,134

)

 

 

7.36

 

Outstanding at September 30, 2024

 

 

3,073,228

 

 

$

6.13

 

 

Summary of Stock-based Compensation Expense for Stock Options and Restricted Stock Units

The following table summarizes the stock-based compensation expense for stock options, restricted stock units and restricted common stock granted to employees and non-employees and from the 2016 ESPP recorded in the Company’s condensed consolidated statements of operations:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Research and development

 

$

518

 

 

$

1,586

 

 

$

2,227

 

 

$

4,236

 

General and administrative

 

 

1,107

 

 

 

1,501

 

 

 

3,304

 

 

 

4,310

 

Restructuring

 

 

 

 

 

168

 

 

 

 

 

 

168

 

Total stock-based compensation expense

 

$

1,625

 

 

$

3,255

 

 

$

5,531

 

 

$

8,714